Autologous hematopoietic stem-cell transplantation for relapsed or refractory Hodgkin's disease in children and adolescents

K. Scott Baker, Bruce Geoffrey Gordon, Thomas G. Gross, Minnie Abromowitch, Elizabeth R. Lyden, James C. Lynch, Julie Marie Vose, James Olen Armitage, Peter F. Coccia, Philip Jay Bierman

Research output: Contribution to journalArticle

67 Citations (Scopus)

Abstract

Purpose: To determine the treatment outcome and clinical factors that are of prognostic significance for children and adolescents with relapsed or refractory Hodgkin's disease (HD) who received treatment with high-dose chemotherapy and autologous hematopoietic stem-cell transplantation (HSCT). Patients and Methods: Fifty-three consecutive children and adolescents 21 years of age or younger with relapsed or refractory HD underwent HSCT. Results: At day 100 after transplantation, 29 patients (55%) were in a complete remission or maintained a continuous complete response, six (11%) had a partial response, and 11 (21%) failed to respond or had progressive disease. The failure-free survival (FFS) at 5 years was 31%, and overall survival was 43%. Twenty-one patients died of progressive HD, and nine died secondary to transplantation-related complications, including two secondary leukemias. Prognostic factors important for FFS were normal pretransplantation lactate dehydrogenase levels (5-year FFS = 42%), compared with patients with elevated LDH levels (5-year FFS = 0%) (P < .001), and disease sensitivity at the time of HSCT with FFS in untreated relapse, sensitive disease, and resistant disease 44%, 35%, and 9%, respectively (P = .06). There was no statistically significant difference in FFS or overall survival between age subgroups that were analyzed (< 13, 13 to 18, 19 to 21) or in comparison with an adult cohort. Conclusion: HSCT is an effective treatment modality that can result in long-term cures and should be considered for children and adolescents with relapsed HD.

Original languageEnglish (US)
Pages (from-to)825-831
Number of pages7
JournalJournal of Clinical Oncology
Volume17
Issue number3
StatePublished - Mar 1999

Fingerprint

Hematopoietic Stem Cell Transplantation
Hodgkin Disease
Survival
Transplantation
Leukemia
Recurrence
Drug Therapy
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Autologous hematopoietic stem-cell transplantation for relapsed or refractory Hodgkin's disease in children and adolescents. / Scott Baker, K.; Gordon, Bruce Geoffrey; Gross, Thomas G.; Abromowitch, Minnie; Lyden, Elizabeth R.; Lynch, James C.; Vose, Julie Marie; Armitage, James Olen; Coccia, Peter F.; Bierman, Philip Jay.

In: Journal of Clinical Oncology, Vol. 17, No. 3, 03.1999, p. 825-831.

Research output: Contribution to journalArticle

@article{618c1f05ad404321b5b1bd317d72a8d5,
title = "Autologous hematopoietic stem-cell transplantation for relapsed or refractory Hodgkin's disease in children and adolescents",
abstract = "Purpose: To determine the treatment outcome and clinical factors that are of prognostic significance for children and adolescents with relapsed or refractory Hodgkin's disease (HD) who received treatment with high-dose chemotherapy and autologous hematopoietic stem-cell transplantation (HSCT). Patients and Methods: Fifty-three consecutive children and adolescents 21 years of age or younger with relapsed or refractory HD underwent HSCT. Results: At day 100 after transplantation, 29 patients (55{\%}) were in a complete remission or maintained a continuous complete response, six (11{\%}) had a partial response, and 11 (21{\%}) failed to respond or had progressive disease. The failure-free survival (FFS) at 5 years was 31{\%}, and overall survival was 43{\%}. Twenty-one patients died of progressive HD, and nine died secondary to transplantation-related complications, including two secondary leukemias. Prognostic factors important for FFS were normal pretransplantation lactate dehydrogenase levels (5-year FFS = 42{\%}), compared with patients with elevated LDH levels (5-year FFS = 0{\%}) (P < .001), and disease sensitivity at the time of HSCT with FFS in untreated relapse, sensitive disease, and resistant disease 44{\%}, 35{\%}, and 9{\%}, respectively (P = .06). There was no statistically significant difference in FFS or overall survival between age subgroups that were analyzed (< 13, 13 to 18, 19 to 21) or in comparison with an adult cohort. Conclusion: HSCT is an effective treatment modality that can result in long-term cures and should be considered for children and adolescents with relapsed HD.",
author = "{Scott Baker}, K. and Gordon, {Bruce Geoffrey} and Gross, {Thomas G.} and Minnie Abromowitch and Lyden, {Elizabeth R.} and Lynch, {James C.} and Vose, {Julie Marie} and Armitage, {James Olen} and Coccia, {Peter F.} and Bierman, {Philip Jay}",
year = "1999",
month = "3",
language = "English (US)",
volume = "17",
pages = "825--831",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "3",

}

TY - JOUR

T1 - Autologous hematopoietic stem-cell transplantation for relapsed or refractory Hodgkin's disease in children and adolescents

AU - Scott Baker, K.

AU - Gordon, Bruce Geoffrey

AU - Gross, Thomas G.

AU - Abromowitch, Minnie

AU - Lyden, Elizabeth R.

AU - Lynch, James C.

AU - Vose, Julie Marie

AU - Armitage, James Olen

AU - Coccia, Peter F.

AU - Bierman, Philip Jay

PY - 1999/3

Y1 - 1999/3

N2 - Purpose: To determine the treatment outcome and clinical factors that are of prognostic significance for children and adolescents with relapsed or refractory Hodgkin's disease (HD) who received treatment with high-dose chemotherapy and autologous hematopoietic stem-cell transplantation (HSCT). Patients and Methods: Fifty-three consecutive children and adolescents 21 years of age or younger with relapsed or refractory HD underwent HSCT. Results: At day 100 after transplantation, 29 patients (55%) were in a complete remission or maintained a continuous complete response, six (11%) had a partial response, and 11 (21%) failed to respond or had progressive disease. The failure-free survival (FFS) at 5 years was 31%, and overall survival was 43%. Twenty-one patients died of progressive HD, and nine died secondary to transplantation-related complications, including two secondary leukemias. Prognostic factors important for FFS were normal pretransplantation lactate dehydrogenase levels (5-year FFS = 42%), compared with patients with elevated LDH levels (5-year FFS = 0%) (P < .001), and disease sensitivity at the time of HSCT with FFS in untreated relapse, sensitive disease, and resistant disease 44%, 35%, and 9%, respectively (P = .06). There was no statistically significant difference in FFS or overall survival between age subgroups that were analyzed (< 13, 13 to 18, 19 to 21) or in comparison with an adult cohort. Conclusion: HSCT is an effective treatment modality that can result in long-term cures and should be considered for children and adolescents with relapsed HD.

AB - Purpose: To determine the treatment outcome and clinical factors that are of prognostic significance for children and adolescents with relapsed or refractory Hodgkin's disease (HD) who received treatment with high-dose chemotherapy and autologous hematopoietic stem-cell transplantation (HSCT). Patients and Methods: Fifty-three consecutive children and adolescents 21 years of age or younger with relapsed or refractory HD underwent HSCT. Results: At day 100 after transplantation, 29 patients (55%) were in a complete remission or maintained a continuous complete response, six (11%) had a partial response, and 11 (21%) failed to respond or had progressive disease. The failure-free survival (FFS) at 5 years was 31%, and overall survival was 43%. Twenty-one patients died of progressive HD, and nine died secondary to transplantation-related complications, including two secondary leukemias. Prognostic factors important for FFS were normal pretransplantation lactate dehydrogenase levels (5-year FFS = 42%), compared with patients with elevated LDH levels (5-year FFS = 0%) (P < .001), and disease sensitivity at the time of HSCT with FFS in untreated relapse, sensitive disease, and resistant disease 44%, 35%, and 9%, respectively (P = .06). There was no statistically significant difference in FFS or overall survival between age subgroups that were analyzed (< 13, 13 to 18, 19 to 21) or in comparison with an adult cohort. Conclusion: HSCT is an effective treatment modality that can result in long-term cures and should be considered for children and adolescents with relapsed HD.

UR - http://www.scopus.com/inward/record.url?scp=0344197155&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0344197155&partnerID=8YFLogxK

M3 - Article

C2 - 10071273

AN - SCOPUS:0344197155

VL - 17

SP - 825

EP - 831

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 3

ER -